Genizon BioSciences Inc. Licenses Ingenuity Systems Pathways Analysis 3.0

October 26, 2005 |

1 min read

Genizon BioSciences and Ingenuity today announced that they have entered into an agreement for the licensing of Ingenuity Pathways Analysis 3.0, significantly accelerating Genizon's genes-to-targets process.

Alliances

MORE ON THIS TOPIC

Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.

Immunology and inflammation

AB Science ends 3 studies in multiple sclerosis, other immune conditions

July 13, 2026

·

2 min read

·

Tristan Manalac

Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.

Antibody-drug conjugates

GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China

July 10, 2026

·

1 min read

·

Gabrielle Masson

A brain hovers over a hand against a yellow-striped background

Huntington’s disease

Roche scraps 2 Huntington’s studies, handing Ionis more bad news

July 10, 2026

·

2 min read

·

Tristan Manalac

Horizontal photo collage picture of people arms in gloves hold work instrument equipment hammer brush nail gun isolated on blue background.

Artificial intelligence

Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report

July 9, 2026

·

2 min read

·

Nick Paul Taylor